Mitigating the impact of the COVID-19 pandemic on available supply for commercialization and programmatic doses required non-COVID-19 vaccines

Overview

In the context of the COVID-19 pandemic and the unprecedented efforts to develop, manufacture, and deliver large quantities of COVID-19 vaccines, the global programmatic doses requirement (PDR) for non-COVID-19 vaccines has been impacted. In parallel risks have emerged for the global supply for these vaccines.

In October 2021, the World Health Organization (WHO), as part of the Market Information for Access (MI4A) project, has sought to assess the potential risks and impacts of the SARS-CoV-2 pandemic and COVID-19 vaccine manufacturing and implementation on PDR and vaccine production.